EMA begins review of SK vaccine.Australian biotech switches gears away from his Covid research – Endpoint News

Another Covid-19 vaccine joins the fray as the EMA launches a conditional marketing authorization application for SK’s vaccine, called Skycovion.

SK Chemicals GmbH has submitted data on the safety and quality of the vaccine to the EMA, as well as data on how well the vaccine induces the production of antibodies against the original strain of SARS-CoV-2.

“Skycovion’s assessment is one of the ongoing assessments of data on Covid-19 vaccines. The EMA and its Scientific Committee are committed to ensuring robust review of all data on COVID-19 vaccines and medicines,” the EMA said in a statement. increase.

According to the EMA, “Skycovion has tiny particles known as nanoparticles that contain part of the spike protein on the surface of SARS-CoV-2.” Designed to identify nanoparticles containing portions of proteins as foreign and create a natural defense against them. ”

SK’s biotech division has been in the vaccine game for some time.

In July of this year, Novavax also signed an agreement with SK Biosciences to manufacture and supply a version of the vaccine specifically designed to protect against Omicron. Korea Herald The contract between the two companies for the supply of prefilled syringes is reportedly worth $29.8 million.

Immuron shifts focus from Covid research

Australian biotech Immuron will refocus its attention on new drug candidates from Covid-19.

The company announced on Friday that it will deprioritize SARS-CoV-2 research and focus on developing more advanced-stage drug candidates.

Immuron said its research results, combined with an ever-evolving therapeutic landscape, presented biotech with a significant challenge to conduct clinical trials of a candidate to treat Covid-19, called IMM-124E.

Immuron reports that its candidate showed neutralizing activity against SARS-CoV-2 and is investigating its antiviral potential. But now the market is dominated by Pfizer’s Pax Rovid, and the company is switching gears.

“Immuron has devoted significant resources to investigating the mechanisms of SARS-CoV-2 protection, but the mechanisms of how IMM-124E provides protection against SARS-CoV-2 viral infection remain unclear. ‘ said the Immuron release.

The company mainly focuses on the treatment of gastrointestinal and gastrointestinal diseases and has two products on the market.

The news isn’t overtly devastating to shareholders, as Immuron’s stock price $IMRN fell more than 1.5% today, but like much of the biotech industry, the company has seen its share price drop 37% since last September. facing

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *